Stevanato Group S.p.A. (STVN) Stock Analysis & Winston Score
Stevanato Group is an Italian company that makes the glass containers and delivery systems used to hold and inject drugs. Its main products include glass vials, syringes, and cartridges that pharmaceutical and biotech companies fill with medicines — including vaccines and injectable biologics. The company is one of the largest suppliers of primary drug packaging in the world. Stevanato earns revenue by selling these containers and drug delivery devices to drugmakers, and it also provides engineering equipment that helps customers build their own packaging lines. It operates globally, with manufacturing in Europe, North America, and Asia, and generates roughly $900 million in annual revenue. Its moat comes from the strict regulatory requirements in drug packaging, which make it hard for customers to switch suppliers once a container is approved for a specific drug. The key growth driver is rising demand for injectable biologics and GLP-1 drugs like semaglutide, though a slowdown in biotech spending or customer inventory destocking could pressure near-term results.
Winston Score: 43/100 — Average
Mixed quality — meaningful strengths and weaknesses.
- Quality: Mixed (11/30)
- Growth: Mixed (8/20)
- Cash Flow: Good (6/10)
- Stability: Exceptional (10/10)
- Valuation: Good (6/10)
- Ownership: Weak (1/15)
Key Facts
Price: $19.17
Market Cap: $5.2B
Sector: Healthcare
Industry: Medical - Instruments & Supplies


